NM26
Atopic Dermatitis
Key Facts
About Numab Innovation
Numab Therapeutics is a Zurich-based biotech pioneering a rational, platform-based approach to design multispecific antibodies with tailored pharmacokinetics. The company's core value proposition lies in its proprietary λ-Cap™ and MATCH™ technologies, which enable the reproducible creation of novel therapeutics intended to overcome limitations of first-generation antibodies. It is advancing a proprietary pipeline led by NM26 for atopic dermatitis while simultaneously validating its platform through multiple high-value collaborations with partners like Boehringer Ingelheim and Kaken Pharmaceutical. The recent appointment of a seasoned CEO with significant commercial and deal-making experience signals a maturation phase focused on pipeline advancement and strategic partnerships.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| HBM7575 (SKB575) | Harbour BioMed | IND Filed |
| ITK inhibitor | Acellera | Pre-clinical |
| Encube-003 | Encube Ethicals | Preclinical |
| ENS-002 (Fermata Derm) | Concerto Biosciences | Pre-clinical |
| Lead Program | MatriSys Bioscience | Phase 1 |
| Atopic Dermatitis Trial | Well Pharma Medical Research | Not Specified |
| MEndoB | Micreos | Pre-clinical |
| Atopic Dermatitis Program | Lxbio Pharmaceuticals | Pre-clinical |
| B244 | AOBiome | Phase 3 |
| CTO1681 | CytoAgents | Pre-clinical |
| DS107 | DS Biopharma | Phase 2 |